Financial comparison between China SXT Pharmaceuticals (NASDAQ:SXTC) and Kiniksa Pharmaceuticals (NASDAQ:KNSA)


China SXT Pharmaceuticals (NASDAQ:SXTC – Get Rating) and Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Rating) are both small cap medical companies, but which is the best investment? We’ll compare the two companies based on institutional ownership strength, risk, analyst recommendations, dividends, profitability, valuation and earnings.


This table compares the net margins, return on equity and return on assets of China SXT Pharmaceuticals and Kiniksa Pharmaceuticals.

Net margins Return on equity return on assets
SXT Pharmaceuticals in China N / A N / A N / A
Kiniksa Pharmaceuticals N / A -69.76% -58.71%

Volatility and risk

China SXT Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. In comparison, Kiniksa Pharmaceuticals has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500.

Insider and Institutional Ownership

15.5% of China SXT Pharmaceuticals shares are held by institutional investors. By comparison, 43.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 54.1% of Kiniksa Pharmaceuticals shares are held by insiders. Strong institutional ownership indicates that large fund managers, endowments, and hedge funds believe a stock is poised for long-term growth.

Analyst Notes

This is a breakdown of recent ratings and price targets for China SXT Pharmaceuticals and Kiniksa Pharmaceuticals, as provided by

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
SXT Pharmaceuticals in China 0 0 0 0 N / A
Kiniksa Pharmaceuticals 0 0 3 0 3.00

Kiniksa Pharmaceuticals has a consensus target price of $30.67, suggesting a potential upside of 168.77%. Given Kiniksa Pharmaceuticals’ likely higher upside, analysts clearly believe that Kiniksa Pharmaceuticals is more favorable than China SXT Pharmaceuticals.

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of China SXT Pharmaceuticals and Kiniksa Pharmaceuticals.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
SXT Pharmaceuticals in China $4.78 million 0.88 -$2.75 million N / A N / A
Kiniksa Pharmaceuticals $38.54 million 20.46 -$157.92 million ($2.30) -4.96

China SXT Pharmaceuticals has higher revenue, but lower revenue than Kiniksa Pharmaceuticals.


Kiniksa Pharmaceuticals beats China SXT Pharmaceuticals on 6 out of 10 factors compared between the two stocks.

SXT Pharmaceuticals Chinese Company Profile (Get an assessment)

China SXT Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the research, development, manufacture, marketing and sales of traditional Chinese medicine tablets (TCMP) in China. It offers advanced, fine and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi and Sharen . The Company offers its products under the brand names Suxuantang, Hui Chun Tang and Tong Ren Tang. As of July 31, 2021, its end customers include 70 pharmaceutical companies, 12 pharmacy chains, and 59 hospitals in 10 provinces and municipalities in China, including Jiangsu, Hubei, Shandong, Guangdong, Liaoning, Anhui, Henan, Jiangxi, Heilongjiang, and Hainan. The company was founded in 2005 and is based in Taizhou, China.

Kiniksa Pharmaceuticals Company Profile (Get an assessment)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, is focused on the discovery, acquisition, development and commercialization of therapeutic drugs for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that has completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in a Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibiting the CD40-CD154 interaction, a T-cell co-stimulatory signal essential for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Get news and reviews for China SXT Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for China SXT Pharmaceuticals and related companies with’s free daily email newsletter.

Source link


Comments are closed.